at Fox Business (Feb 13, 2014)
Elan (ELN +3.8%) intends to spin off its loss-making Neotope drug-discovery unit into a separate publicly traded company, a move that will make Elan immediately profitable and could fuel speculation that it will be a more attractive acquisition target for Biogen (BIIB), which is the firm's partner for its Tysabri multiple sclerosis drug. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at CNBC.com (Dec 16, 2013)
at Fox Business (Sep 19, 2013)
at CNBC.com (Sep 5, 2013)
at MarketWatch.com (Aug 14, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs